Track market-moving stories before they get noisy

Integration brings serialized product verification and traceability directly into medication receiving workflows, intended to enable more efficient pharmacy operations without separate compliance processes.

, /PRNewswire/ -- TraceLink, the world's largest Agentic Business Network for the life sciences and healthcare supply chain, today announced an integration between its Drug Supply Chain Security Act (DSCSA) compliance solution and the pharmacy inventory management systems of Omnicell, Inc. (Nasdaq: OMCL), a leading healthcare technology provider focused on empowering autonomous medication management. This integration is expected to enable hospitals and health systems to manage product verification, traceability, and compliance as part of everyday medication receiving workflows.

Medication shipments received by a hospital or health system pharmacy must be verified, documented, incorporated into inventory, and made available for patient care. When verification or data discrepancies occur, pharmacy teams must also resolve compliance exceptions while maintaining accurate records for regulatory reporting. While the DSCSA established new standards for product verification and traceability, many pharmacy teams still rely on separate compliance tools and manual processes alongside their operational workflows. Managing compliance outside the pharmacy system can add complexity, consume valuable staff time, and create unnecessary interruptions during medication receiving.

Through this integration, hospitals can access TraceLink's DSCSA capabilities directly within Omnicell central pharmacy inventory management workflows. Pharmacy teams can verify serialized products, access traceability information, resolve product verification exceptions, complete compliance reporting, and document receiving activities as medications are received, intended to help reduce manual effort, eliminate disconnected processes, and streamline pharmacy operations without changing established workflows.

TraceLink's DSCSA solution is built on the Integrate-Once™ Agentic Business Network, which links more than 315,000 authenticated entities across life sciences and healthcare and supports hundreds of billions of annual supply chain transactions. By extending this trusted digital infrastructure into hospital pharmacy operations, healthcare organizations are expected to gain immediate access to accurate serialized medicine information exchanged across the broader life sciences supply chain, improve confidence in product authenticity while enabling faster product verification, more efficient compliance exception resolution, and targeted response when recalled products enter the pharmacy.

"Hospital pharmacies shouldn't have to choose between maintaining regulatory compliance and operating efficiently," said Shabbir Dahod, President and CEO of TraceLink. "By integrating TraceLink's trusted DSCSA network with Omnicell's central pharmacy inventory management workflows, we're able to embed verification and traceability directly into medication receiving so pharmacy teams spend less time managing compliance processes and more time ensuring medicines are available for patient care."

Together, TraceLink and Omnicell are working to help hospitals and health systems:

Verify serialized medicines within existing medication receiving workflows. Reduce manual effort associated with DSCSA compliance and audit-ready reporting. Resolve product verification and compliance exceptions more efficiently. Improve traceability to support faster identification of affected recalled products. Increase operational efficiency while supporting medication safety and availability. Sundar Tamma, Vice President of Product Management for Hospital Solutions at Omnicell, said, "Hospital pharmacies continue to face increasing operational demands with limited resources. The integration of TraceLink's solution expands the range of DSCSA integrations available to Omnicell Central Pharmacy Manager customers, providing additional options to support compliance while preserving the efficient workflows pharmacists depend on every day."

As hospital pharmacies continue to modernize medication management, the same trusted serialized medicine information should be able to support broader operational capabilities—including faster compliance exception resolution, targeted recall management, and future intelligent pharmacy workflows—without requiring separate data sources or disconnected compliance systems. This integration represents another step toward embedding trusted supply chain information directly into the systems healthcare providers use every day to deliver safe, efficient patient care.

Learn more about TraceLink's DSCSA compliance solutions for hospitals and health systems.

About TraceLink
TraceLink powers the transformation to an Agentic Supply Chain Operating Model, enabling organizations to perform and improve supply chain work across their business and trading partner networks. The Agentic Supply Chain Operating System, built on the OPUS Platform, brings together Agentic Business Processes, Agentic Control Towers, governed OPUS Agents, with the Integrate-Once™ Agentic Business Network to link systems, end-to-end business transactions, and collaborative peer-to-peer processes to create trusted, real-time operational context. In this agentic environment, humans and agents work together with greater speed, reasoning, control, and accountability to improve organizational productivity, service, inventory, working capital, cost, compliance, quality, resilience, and revenue performance.

Learn more at www.tracelink.com.

About Omnicell
Since 1992, Omnicell has been committed to delivering innovative, outcomes-centric pharmacy and nursing solutions for all settings of care. As an intelligent medication management technology company, Omnicell empowers autonomous medication management by unifying automation and AI-enabled intelligence, optimized by expert services, to drive clinical and business outcomes that are helping to improve efficiency and enhance patient safety for healthcare facilities worldwide.

Learn more at https://www.omnicell.com/ 

OMNICELL and the Omnicell logo are registered trademarks of Omnicell, Inc. or one of its subsidiaries.

SOURCE TraceLink, Inc.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.

Zacks Premium includes access to the Zacks Style Scores as well.

What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.

Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.

Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.

How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.

#1 (Strong Buy) stocks have produced an unmatched +23.8% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.

With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.

For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Omnicell (OMCL - Free Report) Headquartered in Mountain View, CA, Omnicell Inc., develops and markets end-to-end automation solutions for the medication-use process. These automation solutions contain medication and supply dispensing systems, central pharmacy storage, retrieval and packaging solutions, a bedside automation solution, a physician order management solution, a decision support application, and a Web-based procurement application.

OMCL is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.

It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 16.52; value investors should take notice.

Three analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.18 to $2.15 per share. OMCL also boasts an average earnings surprise of +47.3%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, OMCL should be on investors' short list.

Bank of America Corp DE raised its holdings in Omnicell, Inc. (NASDAQ:OMCL – Free Report) by 31.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 580,875 shares of the company’s stock after acquiring an additional 138,537 shares during the period. Bank of America Corp DE owned about 1.28% of Omnicell worth $19,390,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in OMCL. AQR Capital Management LLC boosted its stake in shares of Omnicell by 42.1% during the 1st quarter. AQR Capital Management LLC now owns 17,936 shares of the company’s stock worth $627,000 after buying an additional 5,311 shares during the last quarter. Empowered Funds LLC increased its holdings in shares of Omnicell by 14.3% in the first quarter. Empowered Funds LLC now owns 9,953 shares of the company’s stock valued at $348,000 after purchasing an additional 1,243 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Omnicell by 4.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 124,047 shares of the company’s stock valued at $4,337,000 after buying an additional 4,866 shares during the last quarter. Jane Street Group LLC increased its stake in shares of Omnicell by 201.5% during the first quarter. Jane Street Group LLC now owns 163,664 shares of the company’s stock worth $5,722,000 after purchasing an additional 109,382 shares during the period. Finally, Creative Planning lifted its holdings in shares of Omnicell by 16.7% during the second quarter. Creative Planning now owns 9,390 shares of the company’s stock worth $276,000 after buying an additional 1,347 shares in the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

Analysts Set New Price Targets Several equities analysts have weighed in on the company. Piper Sandler reaffirmed an “overweight” rating and issued a $45.00 price objective (down from $55.00) on shares of Omnicell in a report on Monday, August 3rd. KeyCorp decreased their target price on shares of Omnicell from $70.00 to $65.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. Wall Street Zen upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 10th. Weiss Ratings restated a “hold (c-)” rating on shares of Omnicell in a report on Tuesday, August 4th. Finally, Craig Hallum reissued a “buy” rating and set a $55.00 target price on shares of Omnicell in a research report on Wednesday, April 29th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Omnicell currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.86.

Read Our Latest Research Report on OMCL Omnicell Stock Performance NASDAQ:OMCL opened at $36.43 on Thursday. Omnicell, Inc. has a 52-week low of $29.06 and a 52-week high of $55.00. The firm has a market cap of $1.66 billion, a price-to-earnings ratio of 43.37, a PEG ratio of 0.90 and a beta of 0.98. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.43 and a current ratio of 1.64. The business’s fifty day moving average is $40.47 and its 200 day moving average is $39.80.

Omnicell (NASDAQ:OMCL – Get Free Report) last released its earnings results on Thursday, July 30th. The company reported $0.94 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.47. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.The business had revenue of $312.21 million for the quarter, compared to analysts’ expectations of $310.21 million. During the same quarter in the prior year, the firm earned $0.45 earnings per share. The firm’s revenue was up 7.4% on a year-over-year basis. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Research analysts predict that Omnicell, Inc. will post 1.41 EPS for the current year.

Key Stories Impacting Omnicell Here are the key news stories impacting Omnicell this week:

Positive Sentiment: Zacks raised its FY2026 EPS forecast to $1.49 from $1.27, above the broader consensus estimate of $1.30. It also increased its Q4 2027 estimate to $0.47 from $0.37 and FY2028 estimate to $1.73 from $1.71, suggesting some confidence in longer-term earnings potential. Omnicell analyst estimate report Neutral Sentiment: The estimate changes were made by the same research firm that maintains a “Strong Sell” rating on OMCL, limiting the bullish significance of the upgrades. Omnicell’s current-year outlook remains mixed, with forecast FY2026 earnings of $1.49 followed by lower projected FY2027 earnings of $1.27 before recovering to $1.73 in FY2028. Negative Sentiment: Zacks cut its Q3 2026 EPS forecast to $0.25 from $0.27 and sharply reduced Q4 2026 EPS to $0.07 from $0.31. These downgrades point to weaker earnings momentum in the second half of 2026 and are likely the most immediate negative factor for the stock. Negative Sentiment: Estimates for 2027 were also reduced: Q1 EPS fell to $0.25 from $0.31, Q2 to $0.23 from $0.32, and full-year EPS to $1.27 from $1.34. The Q3 2027 forecast was trimmed slightly to $0.32 from $0.33. Omnicell earnings estimate revisions Negative Sentiment: Zacks also lowered its Q1 2028 EPS estimate to $0.40 from $0.41 and reiterated its “Strong Sell” rating. OMCL remains below its 50-day and 200-day moving averages, indicating continued technical weakness despite the recent modest increase in shares. Omnicell Profile (Free Report)

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.

Featured Articles Five stocks we like better than Omnicell Bloom Energy’s AI Surge Meets a Valuation Reality Check Target Is Winning Shoppers Back—Can the Rally Reach $180? IonQ’s Space Contract Points to a New Frontier for Quantum Investors Is Apple’s AI Strategy Smarter Than Skeptics Think?

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.

Key Takeaways Omnicell shares fell 20.1% in four weeks as booking, margin and refresh-cycle risks weighed on the outlook. OMCL expects $6 million in added memory-chip costs, pressuring product and consolidated gross margins.Omnicell cut recurring-revenue guidance as some consumables opportunities are taking longer to develop. Omnicell, Inc. (OMCL - Free Report) shares have fallen 20.1% in the past four weeks, sharpening the debate over whether the pullback has improved the risk-reward setup or reflects pressures that may persist.

The central tension is clear. Omnicell has raised its 2026 profit outlook, but bookings timing, recurring-revenue growth, component costs and the pace of its product refresh remain less predictable.

OMCL’s Earnings Strength Comes With a CaveatSecond-quarter 2026 adjusted earnings were 94 cents per share, up 108.9% year over year and 95.8% above the Zacks Consensus Estimate. Revenues increased 7.4% to $312.2 million and topped the consensus mark by 0.8%.

Per the Zacks Consensus Estimate, OMCL’s 2026 earnings and revenue is pegged at $2.09 and $1.24 billion, respectively. 

Image Source: Zacks Investment Research

The quarter also benefited from a one-time $15 million tariff refund. Excluding that benefit, non-GAAP EBITDA would have been $52 million, still above the midpoint of prior guidance. Omnicell raised full-year non-GAAP EPS guidance to $2.15-$2.30 and non-GAAP EBITDA guidance to $175-$185 million.

Omnicell Faces New Pressure on Product MarginsMemory-chip supply-demand imbalances are creating a new cost headwind. Omnicell expects about $6 million of incremental memory-chip costs in the second half of 2026, roughly five times the level anticipated at the beginning of the year.

The company expects those costs to reduce full-year consolidated gross margin by about 50 basis points and product gross margin by roughly 80 basis points. With the tariff refund not recurring, continued component inflation or supply constraints could limit further margin expansion.

OMCL’s Booking Visibility Has WeakenedOmnicell widened full-year product-bookings guidance to $425-$560 million as it reassessed the timing of medium-sized and large hospital transactions. Large automation projects can require broad approvals and take multiple quarters or years to close.

Year-end 2026 annual recurring revenue guidance was reduced to $660-$680 million because some consumables opportunities are taking longer to develop. The slower timing matters because recurring revenue is intended to make Omnicell’s business mix more predictable.

Omnicell’s Refresh Cycle Could Take LongerTitan XT remains scheduled to ship in the second half of 2026, but the current XT installed base is younger than the G Series base was during the prior transition. That could reduce replacement urgency even as customers evaluate the new platform.

Competition adds another variable. Becton, Dickinson and Company (BDX) markets BD Pyxis medication-management and automated dispensing systems for health systems, while McKesson Corporation (MCK) offers pharmacy-automation technologies for dispensing, packaging and workflow efficiency. Omnicell is entering a major refresh period while customers are making broad platform comparisons.

OMCL’s Valuation Offers a Potential CounterweightOMCL trades at 1.33X forward 12-month sales, below its five-year median of 1.74X. The multiple is also below the Zacks Medical sector’s 2.24X and the Medical Info Systems sub-industry’s 5.58X.

Image Source: Zacks Investment Research

The discount provides some valuation support, but it does not remove execution risk. A more durable recovery would depend on bookings converting to deployments, recurring revenue improving and the Titan XT refresh translating into revenue over time.

OMCL’s Ratings Still Signal Near-Term CautionThe recent decline has made OMCL less expensive on a sales basis, while the higher 2026 earnings outlook provides an operating offset. Booking uncertainty, memory-chip inflation and refresh-cycle timing still leave the near-term setup unsettled.

OMCL currently carries a Zacks Rank #5 (Strong Sell). Its Growth Score of A, Value Score of B, Momentum Score of B and VGM Score of A indicate favorable characteristics across several investment styles, but the Zacks Rank remains the more important short-term signal because it reflects earnings-estimate revision trends. That combination argues for caution despite the stronger Style Scores.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

On July 31, 2026, Omnicell Inc (OMCL) shares fell 4.7% today, bringing the current price to $35.37. The stock has experienced significant fluctuations over the

Posted by Defense World Staff on Jul 31st, 2026

Dimensional Fund Advisors LP raised its holdings in Omnicell, Inc. (NASDAQ:OMCL – Free Report) by 6.0% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,450,385 shares of the company’s stock after purchasing an additional 137,834 shares during the period. Dimensional Fund Advisors LP owned approximately 5.39% of Omnicell worth $81,791,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Bastion Asset Management Inc. acquired a new stake in shares of Omnicell in the first quarter valued at approximately $4,638,000. Bank of New York Mellon Corp grew its position in Omnicell by 53.8% during the first quarter. Bank of New York Mellon Corp now owns 433,454 shares of the company’s stock worth $14,469,000 after buying an additional 151,679 shares in the last quarter. Illinois Municipal Retirement Fund grew its position in Omnicell by 21.3% during the first quarter. Illinois Municipal Retirement Fund now owns 25,082 shares of the company’s stock worth $837,000 after buying an additional 4,400 shares in the last quarter. Principal Financial Group Inc. increased its stake in Omnicell by 9.8% during the 1st quarter. Principal Financial Group Inc. now owns 296,321 shares of the company’s stock worth $9,891,000 after acquiring an additional 26,441 shares during the period. Finally, Teachers Retirement System of The State of Kentucky increased its stake in Omnicell by 38.2% during the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 35,820 shares of the company’s stock worth $1,195,000 after acquiring an additional 9,906 shares during the period. Institutional investors and hedge funds own 97.70% of the company’s stock.

Key Omnicell News Here are the key news stories impacting Omnicell this week:

Positive Sentiment: Second-quarter results exceeded expectations. Revenue increased approximately 7% year over year to $312 million, while GAAP diluted EPS rose to $0.52 from $0.12 a year earlier. Non-GAAP EPS was reported at $0.94, above the $0.48 consensus estimate. Omnicell Q2 Earnings and Revenues Top Estimates Positive Sentiment: Full-year 2026 earnings outlook was raised. Omnicell now expects non-GAAP EPS of $2.15 to $2.30, above the $1.81 analyst consensus, and expects full-year revenue of approximately $1.225 billion to $1.245 billion. The company also cited demand for connected devices, technical services and SaaS offerings, along with cost controls. Omnicell Q2 Non-GAAP Net Income, Revenue Increase; 2026 Non-GAAP EPS Outlook Lifted Neutral Sentiment: Financial flexibility improved. Omnicell ended June with $292 million in cash and $168 million in debt. It also received $15 million in refunds related to previously paid IEEPA tariffs. Negative Sentiment: Third-quarter guidance fell short of expectations. Management forecast revenue of $301 million to $307 million versus the $312.6 million consensus estimate, while non-GAAP EPS guidance of $0.35 to $0.43 included the consensus estimate only at the top end. The cautious near-term outlook is the primary reason the stock is declining despite the Q2 beat. Omnicell Q2 CY2026: Beats on Revenue but Stock Drops on Weak Guidance Negative Sentiment: Insider selling may add pressure. Recent disclosed activity showed company insiders selling shares, with no reported insider purchases over the past six months. Omnicell Stock Performance Omnicell stock opened at $37.11 on Friday. Omnicell, Inc. has a 12-month low of $28.90 and a 12-month high of $55.00. The company has a quick ratio of 1.29, a current ratio of 1.50 and a debt-to-equity ratio of 0.13. The business’s 50-day moving average price is $42.16 and its two-hundred day moving average price is $41.13. The stock has a market cap of $1.69 billion, a PE ratio of 84.34, a P/E/G ratio of 1.07 and a beta of 0.96.

Omnicell (NASDAQ:OMCL – Get Free Report) last posted its earnings results on Thursday, July 30th. The company reported $0.94 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.47. The firm had revenue of $312.21 million during the quarter, compared to analysts’ expectations of $310.21 million. Omnicell had a net margin of 1.67% and a return on equity of 4.00%. The business’s revenue for the quarter was up 7.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.45 earnings per share. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. As a group, analysts expect that Omnicell, Inc. will post 1.31 earnings per share for the current fiscal year.

Analysts Set New Price Targets A number of analysts have recently weighed in on OMCL shares. KeyCorp upped their target price on Omnicell from $60.00 to $70.00 and gave the company an “overweight” rating in a research report on Tuesday, April 28th. Zacks Research downgraded Omnicell from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Craig Hallum reaffirmed a “buy” rating and set a $55.00 price objective on shares of Omnicell in a research report on Wednesday, April 29th. Weiss Ratings upgraded shares of Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a research note on Thursday, May 7th. Finally, Wall Street Zen upgraded shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 10th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Omnicell currently has an average rating of “Moderate Buy” and an average price target of $59.86.

Read Our Latest Analysis on Omnicell

Insider Activity In other news, EVP Nnamdi Njoku sold 3,090 shares of Omnicell stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $43.22, for a total transaction of $133,549.80. Following the sale, the executive vice president directly owned 154,785 shares of the company’s stock, valued at approximately $6,689,807.70. This trade represents a 1.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Corey J. Manley sold 5,025 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $43.22, for a total transaction of $217,180.50. Following the sale, the executive vice president directly owned 112,783 shares in the company, valued at $4,874,481.26. The trade was a 4.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.92% of the stock is currently owned by company insiders.

Omnicell Profile (Free Report)

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.

Read More Five stocks we like better than Omnicell Microsoft Just Flipped the AI Spending Narrative Overnight Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling? Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINESumitomo Mitsui Financial Group Inc $SMFG Position Increased by Bank of New York Mellon Corp

NEXT HEADLINE »Commerzbank Aktiengesellschaft FI Sells 52,610 Shares of Alphabet Inc. $GOOGL

Omnicell NASDAQ: OMCL reported second-quarter 2026 revenue at the high end of its prior outlook and profitability above expectations, while widening its full-year product bookings range to reflect uncertainty in the timing of customer purchasing decisions for large medication-management platform investments.

Chairman, Chief Executive Officer and Founder Randall Lipps said total revenue was $312 million, while non-GAAP EBITDA reached $67 million and non-GAAP earnings per share totaled $0.94. He said the results reflected operational discipline, improved efficiency and progress toward the company’s strategy of becoming a leader in autonomous medication management.

Get Omnicell alerts:

The company also announced an organizational change, naming Nnamdi Njoku as president and chief operating officer effective July 1. Lipps remains chairman and CEO. Njoku will focus on operational execution, alignment across product strategy and customer engagement, and improving leverage in Omnicell’s profit and loss structure.

Second-Quarter Results Included Tariff Refund Executive Vice President and Chief Financial Officer Baird Radford said product revenue totaled $175 million during the quarter, while service revenue was $137 million. Service growth was supported by specialty pharmacy services, maintenance, support and software-related offerings.

GAAP earnings per share were $0.52, compared with $0.12 in the prior-year period. Omnicell reported a 50% non-GAAP gross margin, which Radford said was primarily driven by a one-time $15 million tariff refund.

Excluding the refund, second-quarter non-GAAP EBITDA would have been $52 million. Radford said the underlying performance still exceeded the midpoint of the company’s earlier guidance, aided by favorable revenue mix, cost management and operating efficiency.

Cash and cash equivalents at quarter-end: $292 million Free cash flow: $56 million, including the tariff refund Second-quarter non-GAAP EBITDA: $67 million Second-quarter non-GAAP earnings per share: $0.94 Radford said Omnicell is continuing to invest in growth initiatives, including leasing programs intended to help customers spread payments over time while providing the company with what it views as attractive lifetime-value economics.

Bookings Outlook Reflects Extended Decision Cycles Omnicell updated its full-year 2026 product bookings guidance to a range of $425 million to $560 million. The upper end of the range was unchanged, but the lower end was reduced as the company cited variability in the timing of medium-sized and large customer transactions.

Radford said the company has visibility into transactions that could support the upper end of the outlook. However, he said it remains difficult to determine which opportunities will close before Dec. 31 as health systems evaluate next-generation platforms and navigate capital approvals, contracting and stakeholder reviews.

“The bottom end of this revised range primarily reflects uncertainty around the timing of purchasing decisions rather than the deterioration in demand for our solutions,” Radford said.

Management said Omnicell’s pipeline exiting the second quarter was meaningfully larger than in recent years, with high engagement from both existing customers and potential competitive conversions. The company said the ongoing transition from its XT platform to Titan XT, combined with a new platform launch from its largest competitor, has increased both the number and size of competitive opportunities.

During the question-and-answer session, Radford said the pipeline includes both medium-sized and large opportunities, existing Omnicell customers considering a transition from XT to Titan XT, and competitive accounts with aging systems. He said such sales processes have historically varied based on customer capital availability, internal approval structures and decision-making timelines.

Platform Rollout and Customer Activity Njoku said Titan XT remains on track to begin shipping in the second half of 2026, while OmniSphere ADS is expected to become generally available in the first half of 2027. Titan XT is Omnicell’s hardware platform, while OmniSphere is its cloud-native platform intended to connect devices, data and workflows across the company’s portfolio.

Omnicell secured its first competitive Titan XT conversion win of the year during the quarter, according to Njoku. A health system in the Southeast selected Titan XT along with AWS, IVX Workflow and other Omnicell solutions as part of a broader medication-management transformation. Njoku said OmniSphere was central to the customer’s decision, while the company’s leasing capabilities also helped differentiate its offering.

The company also cited Titan XT selections by an academic medical center in North Carolina, a Texas-based academic health system and an Arizona regional medical center. In specialty pharmacy, Omnicell said it won a competitive greenfield opportunity with a healthcare provider in northwest Arizona and began two new engagements with health systems in Oregon and Missouri.

Management said it is still early in the competitive process for the new platforms and did not provide specific estimates for the percentage of customers undergoing competitive evaluations. Lipps said customers are increasingly assessing enterprise-wide capabilities, including interoperability, analytics, operational standardization and the ability to support expansion into outpatient settings.

Updated Financial Outlook and Cost Pressures For the third quarter, Omnicell forecast revenue of $301 million to $307 million, non-GAAP EBITDA of $32 million to $37 million, and non-GAAP earnings per share of $0.35 to $0.43. The company expects product revenue of $169 million to $172 million and service revenue of $132 million to $135 million.

The sequential decline in projected EBITDA and earnings per share reflects the absence of the second-quarter tariff refund, lower anticipated revenue and gross margin, and higher operating expenses, partially offset by continued cost management, Radford said.

For full-year 2026, Omnicell now expects:

Total revenue of $1.225 billion to $1.245 billion Product revenue of $690 million to $700 million Service revenue of $535 million to $545 million Year-end annual recurring revenue of $660 million to $680 million Non-GAAP EBITDA of $175 million to $185 million Non-GAAP earnings per share of $2.15 to $2.30 While Omnicell reduced its revenue and annual recurring revenue expectations, it raised its full-year profitability outlook. Radford attributed the higher profitability outlook to the tariff refund and better operating discipline and leverage.

The company also said an imbalance in memory-chip supply and demand is expected to add approximately $6 million of costs in the second half of 2026. Omnicell estimates the issue will reduce full-year consolidated gross margin by about 50 basis points and product gross margin by about 80 basis points.

Njoku said Omnicell continues to work toward broader availability of its IVX platform, guided by internal benchmarks, while also investing in IV workflow and analytics products. He said the company believes the IV medication market will require a range of semi-automated and fully automated solutions.

About Omnicell (NASDAQ:OMCL)Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company's offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell's analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Omnicell Right Now?Before you consider Omnicell, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omnicell wasn't on the list.

While Omnicell currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Omnicell (OMCL - Free Report) came out with quarterly earnings of $0.94 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.45 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +95.83%. A quarter ago, it was expected that this Omnicell Inc. would post earnings of $0.33 per share when it actually produced earnings of $0.55, delivering a surprise of +66.67%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Omnicell, which belongs to the Zacks Medical Info Systems industry, posted revenues of $312.21 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 0.83%. This compares to year-ago revenues of $290.56 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Omnicell shares have lost about 8.6% since the beginning of the year versus the S&P 500's gain of 6.9%.

What's Next for Omnicell?While Omnicell has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Omnicell was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.47 on $312.99 million in revenues for the coming quarter and $1.97 on $1.24 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Info Systems is currently in the top 30% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Senseonics Holdings (SENS - Free Report) , is yet to report results for the quarter ended June 2026. The results are expected to be released on August 6.

This medical technology company is expected to post quarterly loss of $0.55 per share in its upcoming report, which represents a year-over-year change of -37.5%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Senseonics Holdings' revenues are expected to be $13.08 million, up 96.7% from the year-ago quarter.

Key Takeaways Omnicell reports Q2 2026 results on July 30, with revenues seen rising 6.6% and EPS expected to grow 6.7%. OMCL may benefit from OmniSphere adoption, customer wins and Titan XT traction across health systems. Omnicell's Product and Services revenue growth is expected to reflect demand and recurring software momentum. Omnicell (OMCL - Free Report) is set to release second-quarter 2026 results on July 30, before market open. 

In the last reported quarter, the company posted adjusted earnings per share (EPS) of 55 cents, which surpassed the Zacks Consensus Estimate by 66.67%. Omnicell beat on earnings in three of the trailing four quarters and missed on one occasion, the average surprise being 34.65%.

OMCL’s Q2 EstimatesThe Zacks Consensus Estimate for revenues is pegged at $309.6 million, which suggests 6.6% growth from the year-ago reported figure.

The Zacks Consensus Estimate for earnings is pinned at 48 cents per share, which implies a 6.7% rise from the year-ago recorded actuals.

Estimate Revision Trend Ahead of OMCL’s Q2 EarningsEstimates for second-quarter earnings have remained unchanged at 48 cents per share in the past 30 days.

Here’s a brief overview of the company’s performance leading up to this announcement.

Factors Shaping OMCL’s Q2 PerformanceThe company is expected to have delivered another quarter of solid growth, supported by continued execution of its Connected Devices strategy and expanding recurring revenue streams. Demand is likely to have remained strong across inpatient and outpatient pharmacies as well as broader patient care settings, reflecting continued adoption of Omnicell's medication management solutions. 

Second-quarter revenue growth is also expected to have been supported by increasing penetration of OmniSphere, a cloud-native medication management platform, as healthcare providers continue to prioritize enterprise-wide automation, workflow optimization and data-driven medication management. 

The second-quarter top line is also likely to have benefited from continued customer wins among large and complex health systems. The recently launched Titan XT next-generation automated dispensing system is expected to have gained further commercial traction, supported by its integration with the OmniSphere platform. The combined offering is likely to have strengthened Omnicell's value proposition by providing enterprise-wide visibility, guided clinical workflows and a modern cloud-based infrastructure designed for large healthcare organizations.

From a segment perspective, Product revenues are expected to have benefited from sustained demand for the Connected Devices portfolio across both North America and international markets, supported by ongoing capital investments from healthcare providers.

The Zacks Consensus Estimate for Product revenues indicates 5.2% year-over-year growth for the second quarter. 

Service revenues are likely to have remained on a growth trajectory, supported by higher recurring software and service revenues, including continued momentum in Specialty Pharmacy Services. This growth is expected to have been driven by increasing customer adoption of subscription-based and technology-enabled medication management solutions.

The Zacks Consensus Estimate for Services revenues indicates 5% year-over-year growth for the second quarter. 

Omnicell, Inc. Price and EPS SurpriseWhat Our Quantitative Model Predicts for OMCLPer our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates. However, this is not the case here, as you can see below:

Earnings ESP: Omnicell has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Zacks Rank: The company currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank stocks here.

Top MedTech PicksHere are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time around:

Hinge Health Inc. (HNGE - Free Report) has an Earnings ESP of +4.24% and a Zacks Rank #1 at present. The company is expected to release second-quarter 2026 results soon.

In the trailing four quarters, HINGE delivered an average earnings surprise of 179.54%. The Zacks Consensus Estimate for second-quarter EPS implies a decrease of 11.9% from the year-ago quarter’s figure.

Neurocrine Biosciences (NBIX - Free Report) has an Earnings ESP of +40.60% and a Zacks Rank #1 at present. The company is expected to release second-quarter 2026 results soon.

NBIX’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 9.08%. The Zacks Consensus Estimate for the company’s second-quarter EPS calls for an increase of 112.3% from the year-ago quarter’s figure.

West Pharmaceutical Services (WST - Free Report) has an Earnings ESP of +1.09% and a Zacks Rank #2 at present. The company is slated to release second-quarter 2026 results on July 23. 

WST’s earnings beat estimates in each of the trailing four quarters, the average surprise being 19.37%. The Zacks Consensus Estimate for WST’s second-quarter EPS implies a rise of 13% from the year-ago reported figure.

Key Takeaways Omnicell is expanding autonomous pharmacy solutions with SaaS, services and OmniSphere adoption.OMCL is benefiting from health system wins, international expansion and recurring subscription revenue.Omnicell expects tariff costs in 2026, while labor shortages and inflation remain operational challenges. Shares of Omnicell (OMCL - Free Report) have rallied 52.6% over the past year, significantly outperforming the industry’s 20.8% fall and the S&P 500 composite’s 23.9% gain.

Sporting a Zacks Rank #1 (Strong Buy) at present, the healthcare technology company continues to pursue the vision of the autonomous pharmacy, designed to improve medication management outcomes. Growth in SaaS and Expert Services, rising adoption among health systems and international expansion further strengthen its outlook.

Headquartered in Mountain View, CA, Omnicell develops and markets end-to-end automation solutions for the medication-use process. These automation solutions contain medication and supply dispensing systems, central pharmacy storage, retrieval and packaging solutions, a bedside automation solution, a physician order management solution, a decision support application and a Web-based procurement application. The products offered by the company enable care providers to improve patient safety and increase efficiency by lowering costs.

Factors Favoring OMCL’s GrowthOmnicell continues to advance toward its goal of achieving the industry-defined vision of autonomous medication management, which is a roadmap to improving operational efficiencies and ultimately targeting zero-error medication management. Over the past several years, Omnicell has evolved from offering a single-point solution to a platform of products and services and has also secured several wins with major health systems and government health care facilities. OMCL’s ongoing R&D investments across Points of Care, Central Pharmacy and IV Compounding, Specialty Pharmacy and 340B Program and Ambulatory Care market categories are expected to deliver solutions that drive positive medication management outcomes for customers.

Image Source: Zacks Investment Research

The company derives an increasing portion of revenues from its subscription-based SaaS and Expert Services offerings, which include a combination of robotics, smart devices and intelligent software, all optimized by expert services. In recent years, Omnicell has integrated three key acquisitions, such as Specialty Pharmacy Services (formerly ReCept), FDS Amplicare and MarkeTouch Media, LL (merged into EnlivenHealth, Inc), to broaden the offerings. In 2025, SaaS and Expert Services revenues were $259 million.

In the first quarter of 2026, several health systems committed to using Omnicell's inventory optimization service, alongside central pharmacy automation and point-of-care dispensing solutions. The company announced OmniSphere in late 2024, a cloud-native platform designed to unify all Omnicell products under a single, secure infrastructure to make it simpler, safer and more connected to manage medications within a growing health system. EnlivenHealth also continues to gain traction with cross-selling and upselling communication solutions to existing customers.

Healthcare providers outside the United States are becoming increasingly aware of the benefits of automation. There is a substantial demand for adherence packaging equipment outside the domestic market. Omnicell’s international operations include its sales efforts centered in Canada, Europe, the Middle East and the Asia-Pacific regions and supply-chain efforts in Asia. Given the fact that the international market is less than 1% penetrated, with very few hospitals adopting medication control systems, this creates a solid long-term growth opportunity.

Risks for OMCLSimilar to its health-care system partners, Omnicell’s operations continue to be affected by persisting labor shortages as well as increased inflationary costs related to components’ raw materials and freight. The company’s 2026 guidance incorporates an updated estimate of approximately $12 million in tariff-related costs impacting profitability.  

A Glance at OMCL’s EstimatesThe Zacks Consensus Estimate for Omnicell's earnings per share (EPS) is pegged at $1.97 for 2026 and $2.23 for 2027, implying year-over-year growth of 21.6% and 13.2%, respectively. Over the past 60 days, the consensus estimate for 2026 EPS has moved up 5.3%, while the 2027 estimate has increased 2.3%.

Revenues for 2026 are projected to grow 4.9% to $1.24 billion, and another 4.2% to $1.30 billion in 2027.

Other Key StocksSome other top-ranked stocks in the broader medical space are Illumina (ILMN - Free Report) , Align Technology (ALGN - Free Report) and Integra LifeSciences (IART - Free Report) .

Illumina has an earnings yield of 2.8% compared to the industry’s negative 14.6% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 12.2%. ILMN shares have rallied 95.8% compared with the industry’s 25.6% growth over the past year.

ILMN carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Align Technology, carrying a Zacks Rank #2, has an estimated long-term earnings growth rate of 10.3% compared with the industry’s 5.5% growth. Shares of the company have dipped 6.3% against the industry’s 9.6% growth. ALGN’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 7.8%.

Integra LifeSciences, carrying a Zacks Rank #2, has an earnings yield of 13.7% against the industry’s negative 3% yield. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 16.7%. IART shares have rallied 33.8% against the industry’s 10.5% decline over the past year.

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.

The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.

Zacks Premium also includes the Zacks Style Scores.

What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.

Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.

The Style Scores are broken down into four categories:

Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.

VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.

That's where the Style Scores come in.

To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.

As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.

Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Omnicell (OMCL - Free Report) Headquartered in Mountain View, CA, Omnicell Inc., develops and markets end-to-end automation solutions for the medication-use process. These automation solutions contain medication and supply dispensing systems, central pharmacy storage, retrieval and packaging solutions, a bedside automation solution, a physician order management solution, a decision support application, and a Web-based procurement application.

OMCL is a #1 (Strong Buy) on the Zacks Rank, with a VGM Score of B.

It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 20.74; value investors should take notice.

For fiscal 2026, one analyst revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.10 to $1.97 per share. OMCL boasts an average earnings surprise of +34.7%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, OMCL should be on investors' short list.

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.

While many investors like to look for momentum in stocks, this can be very tough to define. There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance. The Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.

Below, we take a look at Omnicell (OMCL - Free Report) , which currently has a Momentum Style Score of A. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions.

It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Omnicell currently has a Zacks Rank of #1 (Strong Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of "A or B" outperform the market over the following one-month period.

You can see the current list of Zacks #1 Rank Stocks here >>>

Set to Beat the Market? In order to see if OMCL is a promising momentum pick, let's examine some Momentum Style elements to see if this Omnicell Inc. holds up.

Looking at a stock's short-term price activity is a great way to gauge if it has momentum, since this can reflect both the current interest in a stock and if buyers or sellers have the upper hand at the moment. It is also useful to compare a security to its industry, as this can help investors pinpoint the top companies in a particular area.

For OMCL, shares are up 14.53% over the past week while the Zacks Medical Info Systems industry is up 1.91% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 27.35% compares favorably with the industry's 7.94% performance as well.

While any stock can see its price increase, it takes a real winner to consistently beat the market. That is why looking at longer term price metrics -- such as performance over the past three months or year -- can be useful as well. Over the past quarter, shares of Omnicell have risen 19.01%, and are up 42.47% in the last year. In comparison, the S&P 500 has only moved 4.92% and 28.12%, respectively.

Investors should also pay attention to OMCL's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. OMCL is currently averaging 627,607 shares for the last 20 days.

Earnings OutlookThe Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock's price movement. Investors should note that earnings estimates are also significant to the Zacks Rank, and a nice path here can be promising. We have recently been noticing this with OMCL.

Over the past two months, 2 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost OMCL's consensus estimate, increasing from $1.78 to $1.98 in the past 60 days. Looking at the next fiscal year, 1 estimate has moved upwards while there have been 1 downward revision in the same time period.

Bottom LineGiven these factors, it shouldn't be surprising that OMCL is a #1 (Strong Buy) stock and boasts a Momentum Score of A. If you're looking for a fresh pick that's set to soar in the near-term, make sure to keep Omnicell on your short list.

Omnicell, Inc. (OMCL) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Omnicell (OMCL - Free Report) closed the last trading session at $43.82, gaining 19.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $61.29 indicates a 39.9% upside potential.

The average comprises seven short-term price targets ranging from a low of $55.00 to a high of $70.00, with a standard deviation of $6.82. While the lowest estimate indicates an increase of 25.5% from the current price level, the most optimistic estimate points to a 59.7% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.

While the consensus price target is highly sought after by investors, the ability and unbiasedness of analysts in setting price targets have long been questionable. And investors making investment decisions solely based on this tool would arguably do themselves a disservice.

However, an impressive consensus price target is not the only factor that indicates a potential upside in OMCL. This view is strengthened by the agreement among analysts that the company will report better earnings than what they estimated earlier. Though a positive trend in earnings estimate revisions doesn't give any idea as to how much the stock could surge, it has proven effective in predicting an upside.

Price, Consensus and EPS Surprise

Here's What You Should Know About Analysts' Price TargetsAccording to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading.

While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why?

They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts.

However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock's price movement. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces.

That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism.

Here's Why There Could be Plenty of Upside Left in OMCLAnalysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason to expect an upside in the stock. That's because empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

The Zacks Consensus Estimate for the current year has increased 43.4% over the past month, as three estimates have gone higher compared to no negative revision.

Moreover, OMCL currently has a Zacks Rank #1 (Strong Buy), which means it is in the top 5% of more than 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock's potential upside in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Therefore, while the consensus price target may not be a reliable indicator of how much OMCL could gain, the direction of price movement it implies does appear to be a good guide.

Key Takeaways Omnicell shares gained 57.3% in a year, outperforming the industry's 30.4% decline.OMCL expanded Autonomous Pharmacy offerings with OmniSphere and launched Titan XT in 2025.Omnicell expects 2026 revenue growth of 4.9% and higher EPS despite tariff-related costs. Omnicell (OMCL - Free Report) has seen impressive growth over the past year, with its shares jumping 57.3%. It has significantly outperformed the industry’s 30.3% fall and the S&P 500 composite’s 33% gain.

Sporting a Zacks Rank #1 (Strong Buy) at present, the healthcare technology company is advancing the vision of Autonomous Pharmacy, supporting improved medication management outcomes. Growth in SaaS and Expert Services, along with the rising adoption of its solutions among health systems, strengthens its outlook. Solid financial health further adds to its appeal. 

Headquartered in Mountain View, CA, Omnicell Inc. develops and markets end-to-end automation solutions for the medication-use process. These automation solutions contain medication and supply dispensing systems, central pharmacy storage, retrieval and packaging solutions, a bedside automation solution, a physician order management solution, a decision support application and a Web-based procurement application. The products offered by the company enable care providers to improve patient safety and increase efficiency by lowering costs. 

Factors Favoring OMCL’s GrowthThe rally in the company’s share price can be linked to the continued momentum across the core businesses. Over the past several years, Omnicell has expanded its business from a single-point solution to a platform of products and services that will help further advance Autonomous Pharmacy, the industry-defined vision to improve operational efficiencies and ultimately target zero-error medication management. Its ongoing R&D investments across Points of Care, Central Pharmacy and IV Compounding, Specialty Pharmacy and 340B Program, and Ambulatory Care market categories are expected to deliver solutions that drive positive medication management outcomes for customers.

Image Source: Zacks Investment Research

To expand its market presence, the company is actively working to grow its product footprint across both inpatient and outpatient care environments, including nursing units, operating rooms and a full spectrum of pharmacy settings. Omnicell’s cloud-native platform, OmniSphere, is designed to bring all its products under a single, secure infrastructure to make it simpler, safer and more connected to manage medications within a growing health system.

In December 2025, the company introduced Titan XT, which offers enterprise-wide visibility, centralized inventory management, guided workflows and a modern infrastructure to support the shift toward autonomous medication management. The launch received a positive early response.

Omnicell derives an increasing portion of revenues from its subscription-based SaaS and Expert Services offerings, which include a combination of robotics, smart devices and intelligent software, all optimized by expert services. In recent years, the company has integrated three key acquisitions, such as Specialty Pharmacy Services (formerly ReCept), FDS Amplicare and MarkeTouch Media, LL (merged into EnlivenHealth, Inc), to broaden the offerings. In the first quarter of 2026, several health systems committed to using Omnicell's inventory optimization service, alongside central pharmacy automation and point-of-care dispensing solutions.

Meanwhile, Omnicell exited the first quarter of 2026 with cash and cash equivalents of $239.2 million and $168 million in total debt, reflecting a healthy liquidity position and balance sheet strength.

Risks for OMCLSimilar to its health-care system partners, Omnicell’s operations continue to be affected by persisting labor shortages as well as increased inflationary costs related to components’ raw materials and freight. In response to changing tariffs, several foreign countries have imposed reciprocal duties on U.S.-manufactured goods. The 2026 guidance incorporates an updated estimate of approximately $12 million in tariff-related costs impacting the P&L. 

A Glance at OMCL’s EstimatesThe Zacks Consensus Estimate for Omnicell’s 2026 and 2027 earnings per share (EPS) is expected to increase 21.6% and 13.2% year over year, respectively, to $1.97 and $2.23. In the past 30 days, the Zacks Consensus Estimate for the company's 2026 EPS has risen 13.2%. 

Revenues for 2026 are projected to grow 4.9% to $1.24 billion, while the same for 2027 are expected to reach $1.30 billion.

Other Key StocksSome other top-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Align Technology (ALGN - Free Report) and Integra LifeSciences (IART - Free Report) .

Globus Medical has an earnings yield of 6.1% compared to the industry’s negative 1.1% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 26.3%. GMED shares have rallied 43.8% against the industry’s 4.8% fall over the past year.

GMED sports a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Align Technology, carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 10.3% for fiscal 2026 compared with the industry’s 9.5% growth. Shares of the company have dropped 4.2% compared to the industry’s 5% rise. ALGN’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 7.8%.

Integra LifeSciences, carrying a Zacks Rank #2, has an earnings yield of 15.7% against the industry’s negative 15.7% yield. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 16.7%. IART shares have rallied 22.8% against the industry’s 4.8% decline over the past year.

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026.

Key Takeaways Omnicell is advancing its Autonomous Pharmacy vision with R&D and major health system wins.Omnicell is growing SaaS and Expert Services, supported by OmniSphere and new automation offerings.OMCL's 2026 EPS estimate rose 5.3% in 30 days, while revenues are projected to grow 4.9%. Omnicell (OMCL - Free Report) is well-poised to grow in the coming quarters as it continues to steadily advance the autonomous pharmacy industry-defined vision for delivering improved medication management outcomes. Growth in SaaS and Expert Services, rising adoption among health systems and international expansion strengthen its outlook. However, macroeconomic headwinds and competitive pressures could weigh on its operating performance.  

Over the past year, this Zacks Rank #1 (Strong Buy) stock has had a remarkable run. OMCL shares have risen 35.7% compared to the 31.6% fall of the industry and the 31.7% growth of the S&P 500 composite.

The renowned healthcare technology company has a market capitalization of $1.91 billion. OMCL’s earnings yield of 4.7% is comfortably above the industry’s negative 1% yield. In the trailing four quarters, Omnicell surpassed earnings estimates thrice and missed on one occasion, the average surprise being 34.7%.

Let’s delve deeper.

Tailwinds for OMCL StockAutonomous Pharmacy Model Holds Potential: The industry-defined vision of Autonomous pharmacy is a roadmap to improving operational efficiencies and ultimately targeting zero-error medication management. Over the past several years, Omnicell has expanded its business from a single-point solution to a platform of products and services that will help further advance the vision.

The company also secured several wins with major health systems and government health care facilities. Omnicell’s ongoing R&D investments across Points of Care, Central Pharmacy and IV Compounding, Specialty Pharmacy, 340B Program and Ambulatory Care market categories are expected to deliver solutions that drive positive medication management outcomes for customers.

Image Source: Zacks Investment Research

Robust Pipeline for SaaS and Expert Services Portfolio: Omnicell derives an increasing portion of revenues from its subscription-based SaaS and Expert Services offerings, which include a combination of robotics, smart devices and intelligent software, all optimized by expert services. In recent years, the company has integrated three key acquisitions, such as Specialty Pharmacy Services (formerly ReCept), FDS Amplicare and MarkeTouch Media, LL (merged into EnlivenHealth, Inc), to broaden the offerings.

The company announced OmniSphere in late 2024, designed to be the connected backbone for all Omnicell products. The same year, it introduced Central Med Automation Service, a subscription-based solution designed to help health systems establish and continuously optimize centralized medication management for consolidated pharmacy service centers (CPSCs) and similar operations. In the first quarter of 2026, several health systems committed to using Omnicell's inventory optimization service, alongside central pharmacy automation and point-of-care dispensing solutions.

Planned Geographic Expansion Another Upside: Outside the United States, healthcare providers are becoming increasingly aware of the benefits of automation. There is a substantial demand for adherence packaging equipment outside the domestic market. Many government and private entities are aware of the progress made over the last several years in the United States and are investing significantly in information technology and automation.

The company’s international operations include its sales efforts centered in Canada, Europe, the Middle East, and the Asia-Pacific regions and supply chain efforts in Asia. Given the fact that the international market is less than 1% penetrated, with very few hospitals adopting medication control systems, Omnicell intends to expand into new markets, which it views as strategic.  

What Ails Omnicell?Escalating Expenses May Strain Margins: Similar to its health-care system partners, the company’s operations continue to be affected by persisting labor shortages as well as increased inflationary costs related to components’ raw materials and freight. Changes in export or import regulations and other trade barriers may have an adverse effect on the company’s business.

Competitive Landscape: Omnicell faces intense competition in the medication management and supply-chain solutions market. Even though the company continues to gain market share from other traditional providers of medication management and supply-chain solutions, major players still pose threats as they spearhead several expansion programs. This increased competition could result in pricing pressure and a reduced margin.

OMCL Stock Estimate TrendThe Zacks Consensus Estimate for OMCL’s 2026 earnings per share (EPS) has jumped 5.3% to $1.97 in the past 30 days. 

The Zacks Consensus Estimate for the company’s 2026 revenues is pegged at $1.24 billion. This suggests a 4.9% increase from the year-ago reported number.

Other Key PicksSome other top-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Align Technology (ALGN - Free Report) and Integra LifeSciences (IART - Free Report) .

Globus Medical has an earnings yield of 6.1% compared to the industry’s negative 1.9% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 26.3%. GMED shares have rallied 30.8% against the industry’s 6.4% fall over the past year.

GMED sports a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Align Technology, sporting a Zacks Rank #1, has an estimated long-term earnings growth rate of 10.3% compared with the industry’s 9.5% growth. Shares of the company have dropped 10.3% against the industry’s 2.3% rise. ALGN’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 7.8%.

Integra LifeSciences, carrying a Zacks Rank #2, has an earnings yield of 15.4% against the industry’s negative 1.9% yield. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 16.7%. IART shares have rallied 21.2% against the industry’s 6.4% decline over the past year.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.

Zacks Premium includes access to the Zacks Style Scores as well.

What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.

Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.

The Style Scores are broken down into four categories:

Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.

Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.

Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.

VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.

It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.

That's where the Style Scores come in.

To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.

As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.

For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Omnicell (OMCL - Free Report) Headquartered in Mountain View, CA, Omnicell Inc., develops and markets end-to-end automation solutions for the medication-use process. These automation solutions contain medication and supply dispensing systems, central pharmacy storage, retrieval and packaging solutions, a bedside automation solution, a physician order management solution, a decision support application, and a Web-based procurement application.

OMCL is a #1 (Strong Buy) on the Zacks Rank, with a VGM Score of B.

Momentum investors should take note of this Medical stock. OMCL has a Momentum Style Score of B, and shares are up 0.6% over the past four weeks.

Three analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.23 to $1.97 per share. OMCL boasts an average earnings surprise of +34.7%.

With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, OMCL should be on investors' short list.

An updated edition of the April 16, 2026, article. 

The American robotics industry has entered a decisive acceleration phase in 2026, with recent months emerging as a landmark across physical AI, surgical systems, defense autonomy, collaborative robotics and elder care — reinforcing a strong investment case for sector leaders, including ABB (ABBNY - Free Report) , Microchip Technology (MCHP - Free Report) , Omnicell (OMCL - Free Report) and Teradyne (TER - Free Report) .

Physical AI Enters the Production EraPhysical AI is now a multi-player race. During National Robotics Week, NVIDIA (NVDA - Free Report) made the open-source Newton Physics Engine 1.0 generally available — co-developed with Google DeepMind and Disney Research — providing a GPU-accelerated simulation foundation for dexterous robot manipulation with accurate collision detection and realistic contact modeling. NVIDIA then unveiled the Isaac GR00T Reference Humanoid Robot at GTC Taipei in late May, pairing a Unitree H2 Plus chassis with Sharpa five-fingered hands and Jetson Thor onboard compute, with commercial availability from Unitree targeted for late 2026.

Google DeepMind has been equally active, as it introduced Gemini Robotics-ER 1.6, upgrading its embodied reasoning model with enhanced spatial reasoning, multi-view success detection and new instrument-reading capabilities developed in collaboration with Boston Dynamics, enabling robots to autonomously read industrial gauges and operate in factories and warehouses. On the venture front, Mind Robotics — a Rivian spinout building AI-powered factory robots — became a unicorn after raising a $500 million Series A in March, and followed up with a further $400 million raise in May to accelerate industrial deployments with partner Rivian.

Manufacturing and Collaborative Robotics AccelerateIn a pivotal consolidation, Skild AI — valued at more than $14 billion — acquired Zebra Technologies' robotics automation division on April 15, bringing the Symmetry Fulfillment orchestration platform under its omni-bodied AI layer. The combined entity now aims to provide a full end-to-end warehouse solution, spanning humanoids for pick-place, robotic arms for packing, AMRs for material movement, and a single orchestration layer to control all form factors.

Meanwhile, OpenAI-backed 1X Technologies launched full-scale production at its 58,000-square-foot NEO humanoid factory in Hayward, CA — the most vertically integrated humanoid robot facility in the United States — targeting 10,000 units in its first year, with consumer shipments planned for 2026 and output scaling to 100,000 units by the end of 2027.

Surgical and Medical Robotics Widen Their ReachIntuitive Surgical reported a 23% revenue increase to $2.77 billion in first-quarter 2026, with da Vinci procedures growing 16% and 431 system placements, including 232 da Vinci 5 units, prompting a guidance raise to 13.5-15.5% full-year procedure growth. CMR Surgical filed a further FDA 510(k) submission in April to expand Versius Plus into benign gynecologic procedures, intensifying competition for Intuitive's dominant market share. The global surgical robotics market is valued at $14.45 billion in 2026, with North America holding a 51% share.

Defense, Space and Elder Care Gain MomentumThe global defense robotics market was valued at $21.2 billion in 2025, with more than 61% of U.S. military modernization projects now incorporating robotic technologies. In elder care, University of New Hampshire researchers, piloting a care robot named Stretch 4 with National Institute on Aging funding, showcased in April how autonomous assistive robots are beginning to address the worsening U.S. caregiver shortage in real home settings. Industry forecasters see consumer and developer humanoid deployments scaling from 2027, with medical and elder care applications forming the largest long-term wave from 2030 onward.

Outlook and Investment OpportunityWith physical AI infrastructure now spanning NVIDIA, Google DeepMind and a new wave of well-funded independents, the first meaningful home deployments and broad warehouse standardization are expected between 2027 and 2028, when the humanoid market is forecast to cross $10 billion — a trajectory supported by falling hardware costs, Robot-as-a-Service models and deepening defense procurement. Across manufacturing, surgical suites, battlefields and care homes, 2026 is laying the foundation for a decisive multi-year expansion.

The Robotics Screen makes it easy to identify high-potential stocks at any given time, just like the ones discussed below. Leveraging advanced tools, the thematic screens identify companies shaping the future, making it easier to capitalize on emerging trends.

Ready to uncover more transformative thematic investment ideas? Explore 30 cutting-edge investment themes with Zacks Thematic Screens and discover your next big opportunity.

ABB presents a compelling robotics investment opportunity anchored by a series of meaningful product advances. In April 2026, ABB Robotics launched the high-speed PoWa cobot family, delivering industry-leading speeds of 5.8 m/s, payloads up to 30kg, and the longest reach in its class, meaningfully lowering the automation barrier for SMEs and large enterprises alike. This Zacks Rank #1 (Strong Buy) company partnered with Jacobi Robotics to bring productized mixed-case palletizing solutions to system integrators. Looking ahead, the imminent divestiture of the Robotics division to SoftBank Group positions ABB Robotics to leverage SoftBank's formidable AI and next-generation computing ecosystem — a powerful catalyst that could supercharge its autonomous, versatile robotics ambitions across industries worldwide. You can see the complete list of today’s Zacks #1 Rank stocks here.

Microchip Technology is emerging as a standout investment in robotics. In April 2026, it earned IEC 62443-4-1 ML2 Industrial Automation and Control System certification, establishing its embedded development processes meet globally recognized secure-by-design standards — a critical differentiator for trusted robotic deployments. This Zacks Rank #1 company also expanded its dsPIC33A Digital Signal Controller family with advanced motor control capabilities, directly powering the joint-level precision that modern robots demand. Last month, next-generation Single Pair Ethernet PHYs integrating Time-Sensitive Networking and functional safety bolstered its industrial connectivity portfolio for robotic systems. With smaller-form-factor PCIe switches expanding its Physical AI and humanoid robotics footprint, MCHP is positioned as a compelling, purpose-built robotics enabler.

Omnicell’s management highlighted Titan XT — its next-generation automated dispensing system — securing initial customer orders, with hardware shipments set to begin in the second half of 2026. The company is actively integrating new robotics innovations and advanced world models with its OmniSphere cloud-native platform, accelerating meaningful progress toward a fully autonomous pharmacy. Expanded deployments with the U.S. Department of Veterans Affairs underscore growing institutional confidence in Omnicell's robotic solutions. With a robust Titan XT demo pipeline and a $2.5 billion-plus replacement cycle opportunity ahead, this Zacks Rank #1 company's robotics strategy positions it strongly for sustained, long-term growth in healthcare automation.

Teradyne's Robotics revenues reached $91 million in first-quarter 2026 — the segment's fourth consecutive quarter of sequential growth, with strong customer engagement across e-commerce, electronics manufacturing and semiconductor end markets. Teradyne Robotics and Flex expanded their collaboration, with Flex both deploying Universal Robots cobots and MiR autonomous mobile robots in its own facilities and manufacturing key robotics components for Teradyne's customers worldwide. Separately, a German court issued a preliminary injunction barring Elite Robots Germany from distributing software alleged to infringe Universal Robots' intellectual property — a decisive win that reinforces the competitive moat around UR's proprietary platform. With a U.S. manufacturing hub set to open in late 2026, this Zacks Rank #1 company's robotics division is well-positioned to capitalize on industrial reshoring and AI-driven automation demand.

Omnicell is rated Buy, with Q1 results showing structural margin improvement and a 660 bps operating margin jump. Q1 revenue grew 15% Y/Y to $310M, with non-GAAP EPS of $0.55 beating guidance by 53% and free cash flow tripling to $39M. Management raised FY 2026 EBITDA guidance, expects margin expansion to outpace revenue growth, and continues share repurchases.

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.

The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.

It also includes access to the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.

Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.

How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.

#1 (Strong Buy) stocks have produced an unmatched +23.7% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.

With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.

That's where the Style Scores come in.

To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.

Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.

Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Omnicell (OMCL - Free Report) Headquartered in Mountain View, CA, Omnicell Inc., develops and markets end-to-end automation solutions for the medication-use process. These automation solutions contain medication and supply dispensing systems, central pharmacy storage, retrieval and packaging solutions, a bedside automation solution, a physician order management solution, a decision support application, and a Web-based procurement application.

OMCL is a #1 (Strong Buy) on the Zacks Rank, with a VGM Score of A.

It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 20.62; value investors should take notice.

Three analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.23 to $1.97 per share. OMCL boasts an average earnings surprise of +34.7%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, OMCL should be on investors' short list.